Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Feb 22, 2024 2:14pm
106 Views
Post# 35893902

up up and away

up up and awayHuzzah...  CRSP up to 90 bucks a share... always worth backing the best in class company. Now heading towards a three bagger now w Azzak. Sad that the only value ONCY seems to have is in tax loss harvesting... LOL... what a company...!!

with respect to ONCY's management, perhaps if the C-suite were not so greedy and aligned their compensation with that of the shareholders, they would have a little more incentive to progress things, and we'd be in a few Phase III trials already.

Compare Coffey et al. with Marcus Lemonis of Bed, Bath and Beyond (BYON, formerly Overstock), He's not taking a penny until the stock reaches $45, currently $27, and will get another payout at $60.

Now that is a leader one can respect and have confidence in... Not the Homer Simpson lookalike we have at the healm of ONCY.. For those who have held a position in this p os for as long as me, you will know that management stating that results are delayed because patients are living longer and longer, is exactly the language used during ONCY's failed Phase III trial for H&N cancer... How sad that they seemed to have learned nothing...
<< Previous
Bullboard Posts
Next >>